Development of<i>in vitro</i>models to demonstrate the ability of PecSys®, an<i>in situ</i>nasal gelling technology, to reduce nasal run-off and drip

Abstract

In both models PecSys significantly reduced the potential for run-off/drip ensuring that more solution remained at the deposition site. In vivo, this enhancement of retention will provide optimum patient acceptability, modulate drug absorption and maximize the ability of drugs to be absorbed across the nasal mucosa and thus reduce variability in drug delivery.